

# ICLIO National Conference

## Care Coordination: General Perspectives on I-O Therapies

Gary I. Cohen, MD

Emeritus Chair, Berman Cancer Institute,  
GBMC

Associate Professor, Oncology,  
SKCCC/JHU

9.30.16

Philadelphia, Pa.



INSTITUTE  
FOR CLINICAL  
IMMUNO-ONCOLOGY



[accc-iclio.org](http://accc-iclio.org)

# Cancer Treatment Interventions

- Surgery (radical, palliative, other?)
- Radiation (PBI vs WBRT, IMRT, SRS, Protons?)
- Medical (Anti-neoplastics?)
- The “Fourth” Modality? (immunotherapy)

# Systemic Therapies for Cancer

- Hormonal
- “CHEMO” (various cytotoxic agents)
- Biologic Therapy (monoclonals → conjugates)
- Targeted Agents
- Immunotherapies

# Spectrum of Immuno-Oncology

- Cytokines: interleukin, interferon
- Myeloid growth factors
- Cellular Therapy: TILs, dendritic, CAR-T, SCT
- Vaccines: Provenge, ?HPV, experimental
- Viral Oncolytics: T-Vec
- Checkpoint inhibitors: CTLA4, PD1, PD-L1

# Making the decision to start I-O therapy

- Value for the patient: response/biomarkers
- Toxicity risk: benefit vs. side effects
- Cost to patient/institution

# Institutional Cost

Pharmacy Audit: GBMC Oncology Pharmacy,  
June 2016

151 items (drugs, supplies)	\$527,972
2 items (ipilimumab/nivo)	\$71,345 (14%)

# Exclusions for I-O therapy

- Performance status
- Financial Toxicity
- Medical co-morbidities
  - ❖ Gastrointestinal
  - ❖ Hepatic/Pulmonary
  - ❖ Autoimmune
  - ❖ Rheumatologic

# Patient Care I-O Team

- **Oncologist**
- **Family/Caregiver**
- **Nursing**
- **Pharmacy**
- **Financial Advisor**
- **Business mgr**



# Patient Care I-O Team

- Oncologist
- Family/Caregiver
- Nursing
- Pharmacy
- Financial Advisor
- Business mgr

## Other medical consultants

- Endocrine
- GI
- Dermatology
- Pulmonary
- Neurology
- Radiology



# Thank you!

**Gary I. Cohen, MD**  
**Berman Cancer Institute, GBMC**  
**Baltimore, MD**



INSTITUTE  
FOR CLINICAL  
IMMUNO-ONCOLOGY

